A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

NCT ID: NCT01881633

Last Updated: 2013-06-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2010-11-30

Brief Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single dosing study with three ascending dose cohorts of ISU302 in healthy subjects.

Conditions

Gaucher Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: DOUBLE

Study Groups

ISU302

15 U/kg I.V. injection

Group Type: EXPERIMENTAL

ISU302

Intervention Type: DRUG

ISU302 30 U/kg

Drug ISU302 I.V. injection

Group Type: EXPERIMENTAL

ISU302

Intervention Type: DRUG

ISU302 60 U/kg

Drug ISU302 I.V. injection

Group Type: EXPERIMENTAL

ISU302

Intervention Type: DRUG

Placebo

ISU302 Placebo I.V. injection

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

ISU302

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male volunteers, aged between ≥ 20 and ≤ 45 years old
• Weight ≥ 50, with calculated body mass index of 17 and 25 kg/m2

• BMI = (Weight [kg])/(height [m])2
• Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and comply with the relevant instructions in written
• Considered ineligible through screening test (such as medical history, physical examination, ECG, safety laboratory test) performed within 35 days prior to study start (dosing of investigational products)

Exclusion Criteria

• With symptoms indicating acute diseases within 28 days prior to start of study (dosing of investigational product)
• History or presence of clinically significant and active cardiovascular, respiratory, renal, endocrine, hematological, gastrointestinal, central nervous system, psychiatric disorder, autoimmune disease, or malignant tumor
• Any medical history that may affect drug absorption, distribution, metabolism and excretion(e.g., inflammatory gastric disease, gastric or intestinal ulcer, hepatic or renal disease)
• With presence of clinically significant allergic disease (including mild allergic rhinitis or allergic dermatitis which does not need medication)
• With presence of clinically significant hypersensitivity to any drugs
• With hemolytic anemia, anemia due to blood loss (Hb < 14g/dL and Hct <42%)
• With the results of safety laboratory test

1. AST (Aspartate Transaminase) or ALT (Alanine Transaminase) > 1.5 times of upper normal limit

2. Total bilirubin > 1.5 times of upper normal limit

• Subject who has immune deficiency or medication with immune suppressants
• Participation in other clinical study within 60 days prior to start of study (dosing of investigational products)
• Use of any drugs, possibly affecting drug metabolizing enzymes, within 1 month prior dosing, or any drugs, possibly affecting the results of clinical trial within 10 days or use of drug was not passes 5 x half-life of drug
• Donated whole blood within 60 days, or transfused within 20 days before the study
• History of alcohol abuse (> 14 units/week) and the subject could not stop drinking alcohol beverage during study period
• Heavy smoker (>10 cigarettes/day) or the subject could not stop smoking during study period
• Unwillingness or inability to follow the procedures outlined in the protocol
• Positive in pregnancy test in urine and unwilling to follow contraception during study period and following 3 months (for female subjects).

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

ISU Abxis Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

ISU-002

Identifier Type: -

Identifier Source: org_study_id